VANI (Vivani Medical) Change In Receivables : $0.00 Mil (TTM As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Vivani Medical Change In Receivables?

Vivani Medical's change in receivables for the quarter that ended in Dec. 2024 was $0.00 Mil. It means Vivani Medical's Accounts Receivable stayed the same from Sep. 2024 to Dec. 2024 .

Vivani Medical's change in receivables for the fiscal year that ended in Dec. 2024 was $-0.25 Mil. It means Vivani Medical's Accounts Receivable increased by $0.25 Mil from Dec. 2023 to Dec. 2024 .

Vivani Medical's Accounts Receivable for the quarter that ended in Dec. 2024 was $0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vivani Medical's liquidation value for the three months ended in Dec. 2024 was $-5.60 Mil.

Vivani Medical Change In Receivables Historical Data

The historical data trend for Vivani Medical's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivani Medical Change In Receivables Chart

Vivani Medical Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Receivables

-0.25

Vivani Medical Quarterly Data
	Dec20	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Receivables	Get a 7-Day Free Trial											-	-	-	-	-

Vivani Medical Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Vivani Medical (NAS:VANI) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vivani Medical's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Vivani Medical's accounts receivable are only considered to be worth 75% of book value:

Vivani Medical's liquidation value for the quarter that ended in Dec. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	18.352	-	23.951	+	0.75 * 0	+	0.5 * 0
=	-5.60

Vivani Medical Change In Receivables Related Terms

Thank you for viewing the detailed overview of Vivani Medical's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivani Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivani Medical Inc (NAS:VANI) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

U5P:Germany

Address

1350 South Loop Road, Alameda, CA, USA, 94502

Website

https://www.vivani.com

Vivani Medical Inc is a preclinical-stage biopharmaceutical company. The company develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near-constant-rate delivery of a broad range of medicines to treat chronic diseases. It has two reporting segments, the Biopharm Division and the Neuromodulation Division. The Biopharm Division includes activities from NPM and Vivani Medical Australia Pty Ltd, and the Neurostimulation Division includes activities from Cortigent and its subsidiary in Switzerland.

Executives

Gregg Williams	director, 10 percent owner	PO BOX 200, WALLED LAKE MI 48390-0200
Donald Dwyer	officer: Chief Business Officer	54 CHERRY FARM LANE, WEST CHESTER PA 19382
Brigid Makes	officer: CFO	20245 SW 95TH AVENUE, TUALATIN OR 97062
Aaron Mendelsohn	director	224 15TH STREET, SANTA MONICA CA 90402
Joachim Eberhard Bolck	10 percent owner	33 CLUB VIEW LANE, ROLLING HILLS ESTATES CA 90274
Lisa Ellen Porter	officer: Chief Medical Officer	778 CORDILLERAS AVE, SAN CARLOS CA 94070
Truc Le	officer: COO	1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn	director, officer: CEO	C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Wilford Dean Baker	director	200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p.	director	3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar	officer: Acting CEO	13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo	officer: Controller	4485 FORESTGLEN CT, MOORPARK CA 93021
Jessy Dana Dorn	officer: VP-Clin & Scientific Affairs	12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Matthew J Pfeffer	director
Patrick Ryan	officer: Chief Operating Officer	C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342